|
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy Clinical research trials and Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy. Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy clinical trial. Subjects typically recieve the finest healthcare available for their Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy  Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
For Condition: Cardiomyopathy, Hypertrophic
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial effects of pacing are evident in sinus rhythm. The long term results of this novel therapy are, however, uncertain. We propose (1) to record the hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing continues to be necessary in patients who have had a substantial relief of their LVOT obstruction. Patients who have had >50% reduction in LVOT pressure gradients will be randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats per minute (DDD switched off), and reevaluated after a six-month period.
Details: DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial effects of pacing are evident in sinus rhythm. The long term results of this novel therapy are, however, uncertain. We propose (1) to record the hemodynamic changes following >4 years of pacing; and (2) to determine whether DDD pacing continues to be necessary in patients who have had a substantial relief of their LVOT obstruction. Patients who have had >50% reduction in LVOT pressure gradients will be randomized to two pacing modalities: DDD at 70 beats per minute and AAI pacing at 70 beats per minute (DDD switched off), and reevaluated after a six-month period.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Group 1: HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at the NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms. Group 2: HCM patients selected from Group 1 who at the follow-up cardiac catheterization are demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT obstruction (greater than 50% reduction in LVOT gradient). Patient who have developed a heart block will be excluded from group 2. Females must have a negative pregnancy test.
Total Enrollment: 120
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960059; 96-H-0059
Study Start Date: April 8, 1996
Record last reviewed: April 21, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001530
Other Cardiomyopathy, Hypertrophic Studies:
1. Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
2. Analysis of Heart Muscle Function in Patients with Heart Disease and Normal Volunteers
3. Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
4. The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients with Hypertrophic Cardiomyopathy
Related Studies:
Other Cardiomyopathy, Hypertrophic Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
|
|
|
|
|
|
|
|
